Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone.

Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, Hao D, Diaz R, Lees-Miller SP, Magliocco AM.

Radiother Oncol. 2010 Nov;97(2):352-9. doi: 10.1016/j.radonc.2010.08.019. Epub 2010 Oct 9.

PMID:
20934765
2.

[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].

Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7. Chinese.

PMID:
19538866
3.

The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.

Hasegawa K, Kato R, Torii Y, Ichikawa R, Oe S, Udagawa Y.

Int J Gynecol Cancer. 2011 Nov;21(8):1479-85. doi: 10.1097/IGC.0b013e31822265e7.

PMID:
21720251
4.

ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.

De Castro G Jr, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH.

Oncol Rep. 2011 Mar;25(3):693-9. doi: 10.3892/or.2011.1133. Epub 2011 Jan 3.

PMID:
21206986
5.

Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.

Kawashima A, Nakayama M, Kakuta Y, Abe T, Hatano K, Mukai M, Nagahara A, Nakai Y, Oka D, Takayama H, Yoshioka T, Hoshida Y, Itatani H, Nishimura K, Nonomura N.

Clin Cancer Res. 2011 Apr 15;17(8):2561-9. doi: 10.1158/1078-0432.CCR-10-1963. Epub 2010 Dec 21.

6.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

PMID:
18977553
7.

ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.

Torii Y, Kato R, Minami Y, Hasegawa K, Fujii T, Udagawa Y.

Anticancer Res. 2014 Jan;34(1):107-15.

PMID:
24403450
8.
9.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.

Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):702-10. Epub 2007 Oct 24.

PMID:
17961161
10.

Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy.

Goyal S, Parikh RR, Green C, Schiff D, Moran MS, Yang Q, Haffty BG.

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):679-84. doi: 10.1016/j.ijrobp.2009.02.050. Epub 2009 May 21.

PMID:
19464815
11.

High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.

Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, Schaefer H, Doerfler W, Bollschweiler E, Dienes HP, Mueller RP, Danenberg PV, Hoelscher AH, Schneider PM.

Clin Cancer Res. 2004 Jun 1;10(11):3794-9.

13.

High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.

Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, Danenberg PV, Harpole DH Jr.

Clin Cancer Res. 2005 Mar 15;11(6):2215-21.

14.

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

Olaussen KA, Mountzios G, Soria JC.

Curr Opin Pulm Med. 2007 Jul;13(4):284-9. Review.

PMID:
17534174
15.

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Vilmar A, Sørensen JB.

Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Review.

PMID:
18804893
16.

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.

Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH.

Lung Cancer. 2008 Jun;60(3):401-7. Epub 2007 Nov 26.

PMID:
18036700
17.

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G.

N Engl J Med. 2007 Feb 22;356(8):800-8.

18.

[Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].

Liu GY, Qu QX, Mi RR, Qi J.

Zhonghua Fu Chan Ke Za Zhi. 2006 May;41(5):339-42. Chinese.

PMID:
16762192
19.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators.

N Engl J Med. 2006 Sep 7;355(10):983-91.

20.

Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.

Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV.

Int J Oncol. 2008 Dec;33(6):1257-62.

PMID:
19020759

Supplemental Content

Support Center